Mural Oncology

NEWS

3D illustration of a T cell killing a cancer cell

Opinion

Ten Years After a Seminal Approval, Immuno-oncology Is Poised for the Next Revolution

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing newer iterations that will take cancer care to the next level.

November 4, 2024

·

4 min read

·

IN THE PRESS

Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference

February 27, 2024

·

1 min read

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 05, 2024

February 5, 2024

·

2 min read

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

January 8, 2024

·

6 min read

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

November 15, 2023

·

7 min read

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

October 31, 2023

·

4 min read

Business

Mural Oncology to Host Investor Webcast on October 17

October 10, 2023

·

3 min read

Business

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

June 1, 2023

·

8 min read

JOBS